Table 3.
Models | Discovery cohort | Validation cohort | |||||
---|---|---|---|---|---|---|---|
iAUCa | Harrell’s C-index | AIC | iAUC | Harrell’s C-index | AIC | ||
TNM stage model b | 0.674 | 0.694 (0.640–0.749) | 615.6 | 0.645 | 0.651 (0.596–0.705) | 742.3 | |
I-score model | 0.584 | 0.592 (0.532–0.651) | 647.4 | 0.592 | 0.588 (0.533–0.644) | 758.6 | |
TNM Stage & I-score model b | 0.699 | 0.711 (0.651–0.772) | 613.5 | 0.673 | 0.679 (0.623–0.736) | 736.4 | |
Clinicopathologic model c | 0.698 | 0.728 (0.676–0.781) | 614.2 | 0.671 | 0.685 (0.627–0.743) | 739.2 | |
Full model c | 0.717 | 0.742 (0.688–0.795) | 610.9 | 0.684 | 0.695 (0.639–0.751) | 734.8 |
Data in parentheses are 95% confidence intervals
iAUC integrated area under the curve, Harrell’s C-index Harrell’s concordance index, AIC Akaike information criterion
aiAUC refers to the integrated area under the ROC curve
b TNM-stage model vs. TNM Stage & I-score model: likelihood ratio P = 0.044
cClinicopathologic model (TMN stage & differentiation grade & adjuvant chemotherapy) vs. Full model: likelihood ratio P = 0.022